Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol vs Desflurane on Circulating Tumor Nucleic Acids in Liver Cancer
NCT05502458Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of propofol injection (veterinary) and desflurane in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Changes of circulating tumor nucleic acids (CK7, ELF3, EGFR and EphB4 mRNA). Started Dec 2020; status: completed.
02
Drugs
propofol injection (veterinary)desflurane
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05502458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502458.